Table 2.
Factors associated with dexamethasone treatment and characteristics associated with the risk of ICU-RTI in the multivariate logistic regression models.
| Variable | Odds Ratio | 95% CI | p-value |
|---|---|---|---|
| Dexamethasone treatment | |||
| Sex | 1.17 | 1.01–1.36 | 0.033 |
| Chronic pulmonary disease | 0.74 | 0.57–0.95 | 0.020 |
| Asthma | 0.70 | 0.50–0.98 | 0.040 |
| Obesity | 1.36 | 1.17–1.58 | <0.001 |
| Diabetes | 1.32 | 1.11–1.57 | 0.001 |
| Days of IMV | 1.01 | 1.00–1.02 | 0.010 |
| Leucocytes, 109 cells/L | 1.01 | 1.00–1.03 | 0.003 |
| C-Reactive Protein, mg/dL | 0.996 | 0.994–0.997 | <0.001 |
| Higher FiO2 support, % | 1.004 | 1.002–1.007 | <0.001 |
| Tocilizumab | 0.61 | 0.49–0.75 | <0.001 |
| Low-middle income country | 1.72 | 1.55–1.90 | <0.001 |
| Risk of ICU-RTI | |||
| IMV | 27.46 | 13.45–56.03 | <0.001 |
| Dexamethasone | 1.64 | 1.37–1.97 | <0.001 |
| pH < 7.4 | 1.35 | 1.13–1.61 | 0.001 |
| PaO2/FiO2 Ratio | 0.996 | 0.995–0.997 | <0.001 |
| Days of IMV | 1.04 | 1.03–1.06 | <0.001 |
| ICU LOS, days | 1.02 | 1.01–1.04 | 0.001 |
| Hospital LOS, days | 0.98 | 0.98–0.99 | <0.001 |
| Middle-income country | 1.97 | 1.39–2.81 | <0.001 |
| Low-middle income country | 4.55 | 3.66–5.66 | <0.001 |